HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients
HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients
复制标题
DOI：
10.1016/j.jfma.2013.10.023
复制
发表时间：
2015-04-01
影响因子：
3.2
通讯作者：
Kao, Jia-Horng
中科院分区：
文献类型：
--
作者：
Peng, Cheng-Yuan;Hsieh, Tsung-Cheng;Kao, Jia-Horng
背景/目的：为了评估治疗中HBV-DNA水平是否可以预测恩替卡韦治疗B e抗原（HBe）阳性慢性B（CH B）patients.Methods：共68例初治HBeAg阳性患者（75%男性，平均年龄46.6 +/- 11.9岁）接受至少2年的恩替卡韦治疗。主要治疗终点为HBeAg消失。治疗中完全病毒学应答定义为血清HBV-DNA
Background/Purpose: To evaluate whether on-treatment HBV-DNA level could predict the treatment response to entecavir in hepatitis B e antigen (HBe)-positive chronic hepatitis B (CHB) patients.Methods: A total of 68 treatment-naive HBeAg-positive patients (75% male, mean age at 46.6 +/- 11.9 years) receiving at least 2 years of entecavir therapy were enrolled. The primary therapeutic endpoint was HBeAg loss. On-treatment complete virological response was defined as serum HBV-DNA